Selective Neuromodulation Using Energy-Efficient Waveforms

• US 20100312304A1
• Filed: 06/05/2009
• Published: 12/09/2010
• Est. Priority Date: 06/05/2009
• Status: Active Grant

• Current Assignee: IntElect Medical, Inc. (Boston Scientific Corporation), Medical College of Wisconsin Incorporated
• Original Assignee: IntElect Medical, Inc. (Boston Scientific Corporation)
• Inventors: BUTSON, Christopher, YORK, Randall
• Granted Patent: US 8,046,077 B2
• Time in Patent Office: Days
• US Class Current: 607/45
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
• CPC Class Codes: A61N 1/378 Electrical supply

Abstract

Methods of selective neuromodulation in a live mammalian subject, such as a human patient. The method comprises applying an electrical signal to a target site in the nervous system, such as the brain, where the electrical signal comprises a series of pulses. The pulses includes a waveform shape that is more energy-efficient as compared to a corresponding rectangular waveform. Non-limiting examples of such energy-efficient waveforms include linear increasing, linear decreasing, exponential increasing, exponential decreasing, and Gaussian waveforms. The parameters for the energy-efficient waveform are chosen to selectively activate neural tissue on the basis of axonal diameter.

Claims

1. A method for selective neuromodulation in a live mammalian subject, comprising:

selecting parameters for an energy-efficient waveform to selectively activate neural tissue on the basis of axonal diameter; and

applying an electrical signal to a site in the nervous system of the subject, wherein the electrical signal comprises pulses having the energy-efficient waveform.

2. The method of claim 1, wherein the width of the energy-efficient waveform is 50 μ

s or longer.

3. The method of claim 1, wherein the energy-efficient waveform is a non-rectangular waveform.

4. The method of claim 1, wherein the energy-efficient waveform is selected from the group consisting of:

linear increasing, linear decreasing, exponential increasing, exponential decreasing, and Gaussian.

5. The method of claim 1, wherein the energy-efficient waveform is linear decreasing, exponential decreasing, or Gaussian.

6. The method of claim 1, wherein the energy-efficient waveform is exponential decreasing or exponential increasing.

7. The method of claim 1, wherein the pulses are current-controlled pulses.

8. The method of claim 1, wherein the pulses are voltage-controlled pulses.

9. The method of claim 1, wherein the pulses are both current-controlled and voltage-controlled.

10. The method of claim 1, wherein the amount of charge injected by the energy-efficient waveform is one-half or less of the amount of charge injected by a corresponding rectangular waveform having the same peak amplitude and same pulse width.

11. The method of claim 1, wherein the nervous system site is a site in the brain involved in motor function.

12. The method of claim 11, wherein the brain site is the thalamus or subthalamic nucleus.

13. The method of claim 1, wherein the energy-efficient waveform is analog or digitally generated.

14. The method of claim 1, wherein the nervous system site is a site in the brain involved in arousal or cognitive function.

15. The method of claim 14, wherein the brain site is the central thalamus, intralaminar nuclei, or subthalamic nuclei.

16. The method of claim 1, wherein the energy-efficient waveform is an energy-optimal waveform.

17. A method of treating a neurologic condition in a live mammalian subject, comprising the method of claim 1.

18. The method of claim 17, wherein the neurologic condition is traumatic brain injury, stroke, or Parkinson'"'"'s disease.

19. The method of claim 17, wherein the neurologic condition involves an impairment of motor function.

20. The method of claim 17, wherein the neurologic condition is Parkinson'"'"'s disease, the site in the nervous system is the subthalamic nucleus, and the energy-efficient waveform is exponential decreasing.

21. The method of claim 17, wherein the neurologic condition involves an impairment of cognitive function.

22. The method of claim 17, wherein the nervous system site is selected from the group consisting of:

basal ganglia, subthalamic nuclei, globus pallidus, internal globus pallidus, external globus pallidus, thalamus, central thalamus, intralaminar nuclei, ventral anterior nuclei, ventral lateral nuclei, ventral posteriolateral nuclei, ventral intermediate nuclei, medial dorsal nuclei, cerebellum, dentatothalamocortical pathway, dentate nuclei, superior cerebellar peduncle, and corpus callosum.

23. The method of claim 17, wherein the neurologic condition is selected from the group consisting of:

stroke, traumatic brain injury, neurodegenerative disease, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, movement disorder, essential tremor, tardive dyskinesia, Tourette'"'"'s syndrome, psychiatric disorder, and depression.

24. A neuromodulation apparatus comprising:

an electrode comprising an electrode contact; and

an implantable pulse generator coupled to the electrode;

wherein the pulse generator is programmed to apply an electrical signal to the electrode contact, the electrical signal comprising pulses having an energy-optimal waveform.